title: Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.
abstract: We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.
authors.affiliation: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, The United States Food and Drug Administration, Silver Spring, MD 20993, USA. paula.gish@fda.hhs.gov
authors.forename: Paula
authors.initials: P
authors.lastname: Gish
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Mosholder
authors.forename: Melissa
authors.initials: M
authors.lastname: Truffa
authors.forename: Rosemary
authors.initials: R
authors.lastname: Johann-Liang
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000367:Age Factors; D002490:Central Nervous System / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D019992:Databases as Topic; D006801:Humans; D007223:Infant; D008333:Mandelic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D009422:Nervous System Diseases / Q000139:chemically induced*; D053206:Nocturnal Enuresis / Q000188:drug therapy; D055815:Young Adult
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin